PatientsVille.com Logo

TIC and Concerta

PatientsVille

TIC Symptoms and Causes

Trigeminal neuralgia (TN) is a type of chronic pain that affects your face. It causes extreme, sudden burning or shock-like pain. It usually affects one side of the face. Any vibration on your face, even from talking, can set it off. The condition may come and go, disappearing for days or even months. But the longer you have it, the less often it goes away.

TN usually affects people over 50, especially women. The cause is probably a blood vessel pressing on the trigeminal nerve, one of the largest nerves in the head. Tumors and multiple sclerosis can also cause TN, but in some cases the cause is unknown.

There is no single test to diagnose TN. It can be hard to diagnose, since many other conditions can cause facial pain. Treatment options include medicines, surgery, and complementary techniques.

NIH: National Institute of Neurological Disorders and Stroke

Check out the latest treatments for TIC

TIC treatment research studies

Concerta clinical trials, surveys and public health registries


Find Drug Side Effect reports



Concerta Side Effects

Aggression (151)
Headache (146)
Suicidal Ideation (145)
Depression (130)
Insomnia (126)
Suicide Attempt (124)
Growth Retardation (119)
Weight Decreased (108)
Tachycardia (106)
Decreased Appetite (102)
Hallucination (94)
Overdose (92)
Chest Pain (91)
Abnormal Behaviour (89)
Psychotic Disorder (85)
Agitation (84)
Anxiety (82)
Nausea (78)
Vomiting (76)
Dizziness (76)
Tic (75)
Hypertension (75)
Convulsion (72)
Product Substitution Issue (71)
Abdominal Pain (65)
Fatigue (63)
Heart Rate Increased (62)
Syncope (57)
Hallucination, Visual (56)
Dyspnoea (55)
Anorexia (54)
Palpitations (53)
Dyskinesia (52)
Intentional Overdose (51)
Arrhythmia (51)
Off Label Use (50)
Disturbance In Attention (49)
Feeling Abnormal (46)
Restlessness (44)
Weight Increased (43)
Tremor (43)
Loss Of Consciousness (42)
Irritability (42)
Psychomotor Hyperactivity (39)
Somnolence (38)
Abdominal Pain Upper (37)
Malaise (37)
Paranoia (36)
Anger (36)
Product Quality Issue (35)

➢ More


Common Meds

Abilify (10132)
Adderall (1304)
Amlodipine (6664)
Amoxicillin (4387)
Benadryl (1568)
Celebrex (12876 )
Celexa (1342)
Cialis (2975)
Cipro (8580)
Citalopram (7792)
Crestor (18839)
Cymbalta (14373)
Doxycycline (1757)
Effexor (7289)
Flexeril (435)
Flomax (2177)
Fluoxetine (4261)
Gabapentin (4593)
Hydrocodone (2469)
Ibuprofen (8222)
Lantus (10968)
Lexapro (3499)
Lipitor (17769)
Lisinopril (8919)
Lyrica (27148)
Medrol (650)
Mirena (41254)
Mobic (957)
Morphine (5356)
Naproxen (538)
Neurontin (6501)
Oxycodone (4438)
Pradaxa (13372)
Prednisone (5926)
Prilosec (2631)
Prozac (1954)
Seroquel (27216)
Simvastatin (8348)
Synthroid (4452)
Tamiflu (5585)
Topamax (3748)
Tramadol (5054)
Trazodone (1458)
Viagra (5394)
Vicodin (1153)
Wellbutrin (6324)
Xanax (2847)
Zocor (5718)
Zoloft(6792)
Zyrtec(1669)

Recent Reviews

Hello my name is Violet and I'm new here. My mother had heart surgery about 8 years ago and they replaced one of her valves. About a week ago she went in for a heart ecko and they are now saying that her valve is starting to back flush. They really

Hi! am looking Operational and Installation manual for this type of x-ray machine Summit AmeriComp control console, with power module SHF 310 and other accessories of it. Well! let me give you this control console picture may be you will aware of

I took Ciplox TZ and I started sweating only while sleeping( night sweating ) and it is tough to sleep for more than 30 mins.will wake up to socked besheet , ATIBIOTICS ARE NOT GOOD DONT USE THEM ! there are soem natural herbal antibiotic

A friend of mine has cancer and the doctors are talking about having surgery and removing the sciatica nerve. My question is will he be a function with this removal.

Adbomen pain and diarria also pain in muscle and legs pain

After Demerol was pushed through my IV. Almost immediately I had a hard time breathing, gasping for breath. Very sweaty and itchy and lightheaded. My blood pressure dropped and medical reports say that I did not have any BP at all at one point. They

After just 7 days of starting pioglitazone(15 mg.daily) ,I developed loss of taste for mainly sugar and salt,but unfortunatyely i couldnot guess pioglitazone as possible cause. I am type 2 diabetic and hypertensive and taking metformin,glimeperide,li

After stoping antibiotics no night sweat no tiredness, I am fully energetic with 66 resting pulse rate !.. THROW AWAY ALL THE ANTIBIOTICS !!

Any side effects from taking neobiotics denfense. Is it good for those with enzema skn problems

Are there anticougulant treatment in Namibia state hospitals?

TIC Clinical Trials and Studies

Treatments might be new drugs or new combinations of drugs, new surgical procedures or devices, or new ways to use existing treatments. The goal of clinical trials is to determine if a new test or treatment works and is safe. Clinical trials can also look at other aspects of care, such as improving the quality of life for people with chronic illnesses. People participate in clinical trials for a variety of reasons. Healthy volunteers say they participate to help others and to contribute to moving science forward. Participants with an illness or disease also participate to help others, but also to possibly receive the newest treatment and to have the additional care and attention from the clinical trial staff.
Rank Status Study
1 Recruiting A Phase 1b Study Evaluating the Safety and Tolerability of ABT-199 in Combination With Rituximab in Subjects With Relapsed Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
Conditions: Small Lymphocytic Lymphoma;   Chronic Lymphocytic Leukemia
Interventions: Drug: ABT-199;   Drug: Rituximab
Outcome Measures: Assess the safety profile, to determine the maximum tolerated dose and Recommended Phase Two Dose of ABT-199 when administered in combination with rituximab (R) in subjects with relapsed chronic Lymphocytic leukemia and small Lymphocytic lymphoma.;   Assess the exploratory efficacy of the combination ABT-199 and rituximab.;   Determination of peak concentration (Cmax), trough concentration (Ctrough) and/or area under the concentration versus time curve (AUC) of ABT-199 and/or Rituximab.
2 Recruiting A Phase II Study of Ofatumumab-Based Induction Chemoimmunotheraphy Followed by Consolidation Ofatumumab Immunotherapy in Previously Untreated Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Conditions: Small Lymphocytic Lymphoma;   CLL (Chronic Lymphocytic Leukemia)
Interventions: Drug: Fludarabine Phosphate;   Biological: Ofatumumab;   Drug: Cyclophosphamide
Outcome Measures: 2-year progression -free survival rate;   response rate (complete response and partial response); toxicity profile; rate of minimal residual disease positivity after completion of induction therapy; rate of conversion to minimal residual disease negativity after consolidation therapy
3 Recruiting R-2cda and Prolongation of Therapy With Rituximab Alone in Chronic Lymphocytic Leukaemia and Small Lymphocytic Lymphoma
Conditions: Chronic Lymphocytic Leukaemia;   Small Lymphocytic Lymphoma
Interventions: Drug: Rituximab;   Drug: Cladribine
Outcome Measures: Response to treatment;   Duration of response
4 Unknown  Multi-center Trial of Revlimid® and Rituximab for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)
Conditions: Chronic Lymphocytic Leukemia;   CLL
Interventions: Drug: Revlimid, rituximab;   Drug: Relapsed or refractory CLL. Lenalidomide and Rituximab
Outcome Measures: iwCLL working group response rate assessed after completion of 7 cycles of treatment.;   adverse events to study treatment;   progression free survival.;   Conversion of MRD-positive complete response or partial response (PR) to a MRD-negative complete response (CR) or complete response (CR) respectively following an additional 6 cycles of Revlimid consolidation;   changes in hematological parameters;   Overall response in relationship to molecular and genetic prognostic factors;   Chronic Lymphocytic Leukemia up-regulated protein 1 (CLLU1);   overall survival.;   treatment free survival.
5 Recruiting Akt Inhibitor MK2206, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Conditions: B-cell Chronic Lymphocytic Leukemia;   Recurrent Small Lymphocytic Lymphoma;   Refractory Chronic Lymphocytic Leukemia
Interventions: Drug: Akt inhibitor MK2206;   Biological: rituximab;   Drug: bendamustine hydrochloride;   Other: laboratory biomarker analysis
Outcome Measures: MTD of Akt inhibitor MK2206 defined as the dose level below the lowest dose that induces dose-limiting toxicity in at least one-third of patients graded according to NCI Common Terminology Criteria for Adverse Events (CTCAE) version 4.0 (Phase I);   Proportion of complete response defined to be a CR or CRi noted as the objective status (Phase II);   Overall response rate, estimated by the total number of complete or partial responses (CR, CRi, CCR, nPR, or PR) divided by the total number of evaluate patients;   Duration of response;   Treatment-free survival;   Biomarker analysis (IgVH gene mutation, CD38, CD49d, ZAP-70 and FISH status);   Minimal-residual disease
6 Not yet recruiting Curcumin and Cholecalciferol in Treating Patients With Previously Untreated Stage 0-II Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Conditions: Contiguous Stage II Small Lymphocytic Lymphoma;   Noncontiguous Stage II Small Lymphocytic Lymphoma;   Stage 0 Chronic Lymphocytic Leukemia;   Stage I Chronic Lymphocytic Leukemia;   Stage I Small Lymphocytic Lymphoma;   Stage II Chronic Lymphocytic Leukemia
Interventions: Dietary Supplement: curcumin;   Dietary Supplement: cholecalciferol;   Other: laboratory biomarker analysis;   Other: pharmacological study
Outcome Measures: Overall response rate (biologic response rate + complete response [CR] + partial response [PR]) based on NCI-WG (for CLL) and Cheson criteria (for SLL);   Time to first cytotoxic treatment;   Progression free survival;   Overall survival;   Duration of response
7 Recruiting Lenalidomide and Vaccine Therapy in Treating Patients With Early-Stage Asymptomatic Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Conditions: B-cell Chronic Lymphocytic Leukemia;   Bacterial Infection;   Contiguous Stage II Small Lymphocytic Lymphoma;   Noncontiguous Stage II Small Lymphocytic Lymphoma;   Stage 0 Chronic Lymphocytic Leukemia;   Stage I Chronic Lymphocytic Leukemia;   Stage I Small Lymphocytic Lymphoma;   Stage II Chronic Lymphocytic Leukemia
Interventions: Biological: pneumococcal polyvalent vaccine;   Drug: lenalidomide;   Other: pharmacological study;   Other: laboratory biomarker analysis
Outcome Measures: Proportion of patients who achieve an antibody response;   Seroconversion rates;   CR rate;   Time to first treatment as defined by IWCLL 2008 criteria;   Overall survival;   Progression-free survival as defined by IWCLL 2008 criteria;   Incidence of adverse events according to NCI CTCAE version 4;   Pharmacokinetic (PK) parameters of lenalidomide;   Change in serum immunoglobulin;   Antibody titre levels for each of the serotypes;   Change in anti-tumor antibody levels
8 Recruiting Natural History Study of Monoclonal B Cell Lymphocytosis and Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Conditions: B-Cell Chronic Lymphocytic Leukemia;   Monoclonal B-Cell Lymphocytosis;   Lymhoma, Small Lymphocytic;   Chronic Lymphocytic Leukemia
Intervention:
Outcome Measure:
9 Recruiting Lenalidomide and Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Conditions: ProLymphocytic Leukemia;   Recurrent Small Lymphocytic Lymphoma;   Refractory Chronic Lymphocytic Leukemia
Interventions: Drug: ibrutinib;   Drug: lenalidomide;   Other: pharmacological study;   Other: laboratory biomarker analysis
Outcome Measures: MTD of lenalidomide when combined with ibrutinib defined as the highest dose in which less than or equal to 1/6 patients have dose limiting toxicity;   Response rates;   Remission/response duration
10 Recruiting Phase 1 Study of TG02 Citrate in Patients With Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
Conditions: Chronic Lymphocytic Leukemia;   Small Lymphocytic Lymphoma
Intervention: Drug: TG02 citrate
Outcome Measures: Maximum Tolerated Dose;   Safety
11 Recruiting Safety Study of CC-292 and Lenalidomide in Subjects With Chronic Lymphocytic Leukemia/ Small Lymphocytic Lymphoma
Condition: Leukemia Lymphocytic Chronic B-Cell
Interventions: Drug: CC-292;   Drug: Lenalidomide
Outcome Measures: Adverse Events;   Efficacy;   PK-Cmax;   PK-Tmax;   PK-λz;   PK-t1/2;   PK-AUC (0-t);   PK-AUC0-∞
12 Recruiting Pyrimethamine for the Treatment of Relapsed Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Conditions: Chronic Lymphocytic Leukemia;   Small Lymphocytic Leukemia
Intervention: Drug: pyrimethamine
Outcome Measures: Phase I: To determine the maximum tolerated dose and recommended Phase 2 dose of pyrimethamine in relapsed CLL/SLL;   Phase II: To determine the overall response rate of pyrimethamine in relapsed CLL/SLL.;   To assess the toxicity profile of pyrimethamine in relapsed CLL/SLL, both acutely and over prolonged daily dosing.;   To determine pyrimethamine levels in vivo with prolonged dosing.;   To determine the progression-free survival following pyrimethamine for the treatment of relapsed CLL/SLL
13 Recruiting Dasatinib With Fludarabine and Rituximab in Relapsed and Refractory Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
Conditions: Chronic Lymphocytic Leukemia;   Small Lymphocytic Lymphoma
Interventions: Drug: dasatinib;   Drug: Rituximab;   Drug: fludarabine
Outcome Measures: Response rate;   Duration of Response;   Progression-Free and Overall Survival;   Toxicities
14 Recruiting Phase I and II Study of Auranofin in Chronic Lymphocytic Leukemia (CLL)
Conditions: Chronic Lymphocytic Leukemia (CLL);   Small Lymphocytic Lymphoma;   Leukemia, ProLymphocytic
Intervention: Drug: auranofin
Outcome Measures: Response Rate;   type, incidence, severity, seriousness and relationship to auranofin of adverse events and any laboratory abnormalities
15 Recruiting Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Conditions: Anemia;   Fever, Sweats, and Hot Flashes;   Stage I Chronic Lymphocytic Leukemia;   Stage I Small Lymphocytic Lymphoma;   Stage II Chronic Lymphocytic Leukemia;   Stage II Small Lymphocytic Lymphoma;   Stage III Chronic Lymphocytic Leukemia;   Stage III Small Lymphocytic Lymphoma;   Stage IV Chronic Lymphocytic Leukemia;   Stage IV Small Lymphocytic Lymphoma;   Weight Changes
Interventions: Drug: ibrutinib;   Drug: fludarabine phosphate;   Drug: cyclophosphamide;   Biological: rituximab;   Procedure: quality-of-life assessment;   Other: laboratory biomarker analysis
Outcome Measures: PFS;   Change in quality of life assessed using Functional Assessment of Cancer Therapy -Leukemia (FACT-Leu) Trial Outcome Index (TOI);   OS;   Incidence of toxicity, defined as adverse events that are classified as either possibly, probably, or definitely related to study treatment, graded according to NCI Common Terminology for Adverse Events version 4.0;   Change in FACT-Leu TOI score;   Impact of CLL on QOL;   Adherence to prescription assessed by the Moriskey Adherence Scale (Arm A only)
16 Recruiting Phase 1 Dose Escalation Study in Chronic Lymphocytic Leukemia and Non-hodgkin Lymphoma
Conditions: Chronic Lymphocytic Leukemia (CLL);   Small Lymphocytic Lymphoma (SLL);   B-cell Non Hodgkin Lymphoma (NHL)
Intervention: Drug: PRT062070
Outcome Measures: Maximum tolerated dose (MTD) of PRT062070 in patients with relapsed/refractory CLL, SLL or B-cell NHL.;   Frequency and severity of dose limiting toxicity (as classified by Common Terminology Criteria for Adverse Events (CTCAEv4) by dose level.;   Peak plasma concentration (Cmax) and area under the plasma concentration versus time curve (AUC) of PRT602070.
17 Recruiting Fludarabine Phosphate, Radiation Therapy, and Rituximab in Treating Patients Who Are Undergoing Donor Stem Cell Transplant Followed by Rituximab for High-Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Conditions: B-cell Chronic Lymphocytic Leukemia;   ProLymphocytic Leukemia;   Recurrent Small Lymphocytic Lymphoma;   Refractory Chronic Lymphocytic Leukemia;   Stage III Chronic Lymphocytic Leukemia;   Stage III Small Lymphocytic Lymphoma;   Stage IV Chronic Lymphocytic Leukemia;   Stage IV Small Lymphocytic Lymphoma;   T-cell Large Granular Lymphocyte Leukemia
Interventions: Drug: fludarabine phosphate;   Biological: rituximab;   Radiation: total-body irradiation;   Procedure: allogeneic hematopoietic stem cell transplantation;   Procedure: peripheral blood stem cell transplantation;   Drug: cyclosporine;   Drug: mycophenolate mofetil;   Other: laboratory biomarker analysis;   Other: pharmacological study
Outcome Measures: Survival;   Proportion of patients achieving complete response and partial response (overall response rate);   Incidence of regimen-related toxicity and infections;   Incidence of treatment-related mortality;   Incidence of grade II-III and III-IV acute GVHD and chronic GVHD;   Comparison of survival, serious adverse events, and B-cell and T-cell immune reconstitution with historical data;   Pharmacokinetics of rituximab;   Donor and host polymorphisms of the FCgammaRIIIa receptor and CD32 and their impact on disease response and relapse;   Graft-versus-leukemia analysis by mechanism of disease resistance in relapsed or non-responding patients and isolation of donor cytotoxic T lymphocytes specific for host minor histocompatibility antigens
18 Recruiting PCI-32765 (Ibrutinib) in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or B-cell ProLymphocytic Leukemia
Conditions: ProLymphocytic Leukemia;   Recurrent Small Lymphocytic Lymphoma;   Refractory/Relapsed Chronic Lymphocytic Leukemia
Interventions: Drug: ibrutinib;   Other: Correlative laboratory samples;   Other: quality of life assessment
Outcome Measures: Determine the 2 year progression-free survival (PFS) of single agent PCI-32765 in patients with relapsed and refractory CLL.;   Overall response rate (ORR), duration of response (DOR) overall survival (OS),assessed using the Revised International Workshop on Chronic Lymphocytic Leukemia (IWCLL) working group guidelines;   Frequency, severity and relatedness of adverse events, graded according to the NCI Common Terminology Criteria for Adverse Events (CTCAE) version 4.0;   Pharmacodynamic, cytokine, primary/secondary resistance studies of ibrutinib, and baseline profiling of tumor cells;   Patient reported emotional distress and health related quality of life;   Decrease in immune suppression of CLL cells;   Effectiveness of ibrutinib bridging patients to allogeneic stem cell transplant and outcome of patients following this intervention
19 Recruiting Safety Study of CC-292 and Rituximab in Subjects With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Condition: Leukemia Lymphocytic Chronic B-Cell
Interventions: Drug: CC-292;   Drug: Rituximab
Outcome Measures: Adverse Events;   PK-Cmax;   PK-Tmax;   PK-λz;   PK-t1/2;   PK-AUC (0-t);   PK-AUC0-∞;   Efficacy
20 Recruiting Phase II MOR00208 in Combination With Lenalidomide for Patients With Relapsed or Refractory CLL, SLL or PLL or Older Patients With Untreated CLL, SLL or PLL
Conditions: Contiguous Stage II Small Lymphocytic Lymphoma;   Noncontiguous Stage II Small Lymphocytic Lymphoma;   ProLymphocytic Leukemia;   Recurrent Small Lymphocytic Lymphoma;   Refractory Chronic Lymphocytic Leukemia;   Stage I Chronic Lymphocytic Leukemia;   Stage I Small Lymphocytic Lymphoma;   Stage II Chronic Lymphocytic Leukemia;   Stage III Chronic Lymphocytic Leukemia;   Stage III Small Lymphocytic Lymphoma;   Stage IV Chronic Lymphocytic Leukemia;   Stage IV Small Lymphocytic Lymphoma
Interventions: Biological: MOR00208;   Drug: lenalidomide;   Other: Correlative Studies
Outcome Measures: Proportion of patients who achieve a response (i.e. CR, complete response with incomplete recovery [CRi], nPR, or PR), as defined according to the IWCLL 2008 criteria;   ORR;   PFS;   Time to next treatment;   OS;   Results of FISH;   Results of stimulated karyotype;   Zap-70 methylation;   IgVH mutational status;   Effects of combined therapy with MOR00208 and lenalidomide on CD4+ T cells using flow cytometry during the course of protocol therapy;   Effects of combined therapy with MOR00208 and lenalidomide on CD8+ T cells during the course of protocol therapy by flow cytometry;   Effects of combined therapy with MOR00208 and lenalidomide on NK cells during the course of protocol therapy by flow cytometry;   Changes in IL-21R expression;   Changes in expression of select genes associated with B-cell activation;   Incidence of adverse events as graded per the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0;   Tolerability assessed by the number of patients who require dose modifications and/or dose delays